tbuckley/cabot-search huggingface dataset:
Supporting insulin initiation in type 2 diabetes in primary care: results of the Stepping Up pragmatic cluster randomised controlled clinical trial
Authors: John Furler, David O’Neal, Jane Speight, Jo-Anne Manski-Nankervis, Alexandra Gorelik, Elizabeth Holmes-Truscott, Louise Ginnivan, Doris Young, James Best, Elizabeth Patterson, Danny Liew, Leonie Segal, Carl May, Irene Blackberry
Journal: BMJ (2017)

Objective To compare the effectiveness of a novel model of care ("Stepping Up") with usual primary care in normalising insulin initiation for type 2 diabetes, leading to improved glycated haemoglobin (HbA1c) levels.Design Cluster randomised controlled trial.Setting Primary care practices in Victoria, Australia, with a practice nurse and at least one consenting eligible patient (HbA1c ≥7.5% with maximal oral treatment).Participants 266 patients with type 2 diabetes and 74 practices (mean cluster size 4 (range 1-8) patients), followed up for 12 months.Intervention The Stepping Up model of care intervention involved theory based change in practice systems and reorientation of the roles of health professionals in the primary care diabetes team. The core components were an enhanced role for the practice nurse in leading insulin initiation and mentoring by a registered nurse with diabetes educator credentials.Main outcome measures The primary endpoint was change in HbA1c. Secondary endpoints included the proportion of participants who transitioned to insulin, proportion who achieved target HbA1c, and a change in depressive symptoms (patient health questionnaire, PHQ-9), diabetes specific distress (problem areas in diabetes scale, PAID), and generic health status (assessment of quality of life instrument, AQoL-8D).Results HbA1c improved in both arms, with a clinically significant between arm difference (mean difference -0.6%, 95% confidence interval -0.9% to -0.3%), favouring the intervention. At 12 months, in intervention practices, 105/151 (70%) of participants had started insulin, compared with 25/115 (22%) in control practices (odds ratio 8.3, 95% confidence interval 4.5 to 15.4, P<0.001). Target HbA1c (≤7% (53 mmol/mol)) was achieved by 54 (36%) intervention participants and 22 (19%) control participants (odds ratio 2.2, 1.2 to 4.3, P=0.02). Depressive symptoms did not worsen at 12 months (PHQ-9: -1.1 (3.5) v -0.1 (2.9), P=0.05). A statistically significant difference was found between arms in the mean change in mental health (AQoL mental component summary: 0.04 (SD 0.16) v -0.002 (0.13), mean difference 0.04 (95% confidence interval 0.002 to 0.08), P=0.04), favouring the intervention, but no significant difference in physical health (AQoL physical component summary: 0.03 (0.15) v 0.02 (0.13)) nor diabetes specific distress (5.6 (15.5) v -2.4 (15.4)). No severe hypoglycaemia events were reported.Conclusions The Stepping Up model of care was associated with increased insulin initiation rates in primary care, and improvements in glycated haemoglobin without worsening emotional wellbeing.Trial registration Australian and New Zealand Clinical Trials Registry ACTRN12612001028897.
A Phase I/II Study of Bortezomib and Low Dose Intravenous Melphalan (BM) for Relapsed Multiple Myeloma.
Authors: Rakesh Popat, Heather E. Oakervee, Nicola Foot, Samir Agrawal, Patricia Smith, Charles Craddock, Catherine Williams, Supratik Basu, Jamie D. Cavenagh
Journal: Blood (2005)
Influence of JAK2V617F Allele Burden on Hematological Response in the Treatment of Polycythemia Vera
Authors: Dzhariyat Shikhbabaeva, Vasily Shuvaev, Regina Golovchenko, Vera Udaleva, Mikhail Fominykh, Irina I Zotova, Lyubov Polushkina, Irina Martynkevich, Kudrat Abdulkadyrov
Journal: Blood (2016)
Breakthrough C. parapsilosis (Cp) and C. guillermondii (Cg) Blood Stream Infections in Allogeneic Hematopoetic Stem Cell (HSC) Recipients Receiving Long Term Caspofungin (C) Therapy.
Authors: Nabil Kabbara, Claire Lacroix, Marie Robin, Vanderson Rocha, Regis Peffault de Latour, Helene Esperou, Agnes Devergie, Eliane Gluckman, Gerard Socie, Patricia Ribaud
Journal: Blood (2006)
Frequency and Relevance of CD10+CD19+ Hematogones after Allogeneic Stem Cell Transplantation.
Authors: Axel Nogai, Eckhard Thiel, Thomas Burmeister, Susanne Ganepola, Rita Lippoldt, Igor W. Blau, Olga O. Blau, Carola Tietze-Bürger, Lutz Uharek, Stefan Schwartz
Journal: Blood (2008)
Carotid Plaque Lipid Content and Fibrous Cap Status Predict Systemic CV Outcomes
Authors: Jie Sun, Xue-Qiao Zhao, Niranjan Balu, Moni B. Neradilek, Daniel A. Isquith, Kiyofumi Yamada, Gádor Cantón, John R. Crouse, Todd J. Anderson, John Huston, Kevin O’Brien, Daniel S. Hippe, Nayak L. Polissar, Chun Yuan, Thomas S. Hatsukami
Journal: JACC. Cardiovascular imaging (2017)
Comparison of Busulfan and Cyclophosphamide (Bu-Cy)-Based Standard Myeloablative Conditioning (MAC) Vs. Fludarabine and Busulfan (Flu-Bu)-Based Reduced-Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) From An HLA Identical Sibling Donor for Acute Myeloid Leukemia (AML) Patients in First Complete Remission (CR1) Aged &gt;40 Years: a Retrospective Analysis From the Acute Leukemia Working Party of EBMT.
Authors: Mohamad Mohty, Myriam Labopin, Gerard Socié, Noel-Jean Milpied, Michel Attal, Didier Blaise, Olle Ringden, Paul Brown, Brinch Lorentz, Mats L Brune, Rose-Marie Hamladji, Rafael F Duarte, Arnon Nagler, Vanderson Rocha
Journal: Blood (2009)
Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: To Allogeneic Stem Cell Transplantation or Not? a Single Center Experience
Authors: xiao-Jun Huang, Jing Wang, Qian Jiang, Huan Chen, Lanping Xu, Xiao-Hui Zhang, Ya-Zhen Qin, Hao Jiang, Jin Lu, Kai-Yan Liu, Bin Jiang
Journal: Blood (2016)
Abstract IA27: Small cell lung cancer circulating tumor cell-derived explants: A new preclinical platform for examining drug response
Authors: Kristopher K. Frese, Christopher Morrow, Crispin Miller, Fiona Blackhall, Caroline Dive
Journal: Clinical Cancer Research (2016)

Abstract Small cell lung cancer (SCLC) is a highly aggressive disease with a 5 year survival of 5% that has remained relatively unchanged for the past several decades. Despite a robust response the first line chemotherapy, 95% of patients relapse within a few months. Due in part to the paucity of SCLC tissue samples available for preclinical studies, the molecular mechanisms unpinning disease relapse and acquired drug resistance are poorly understood. Non-invasive collection of liquid biopsies have proven useful in for tumor diagnosis and monitoring, however they have traditionally provided limited utility in mechanistically interrogating drug sensitivity. We have recently demonstrated that SCLC circulating tumor cells (CTCs) are tumorigenic in mice and the resulting patient CTC-derived explants (CDX) mirror patients' disease. We have developed a library CDX where CTCs were enriched either at baseline or upon progression from chemosensitive or chemorefractory SCLC patients. Strikingly, these CDX faithfully recapitulate the histological, genomic, and chemoresistance aspects of patient tumors, suggesting they may be a suitable platform for identifying new drug targets, testing novel drugs, and exploring drug resistance mechanisms. Studies underway are aimed at providing mRNA and genomic DNA analysis from the same CTC or CDX sample to establish direct linkage between mutational changes and emergent mRNA profiles to gain insights into mechanisms underpinning treatment responses. Citation Format: Kristopher K. Frese, Christopher Morrow, Crispin Miller, Fiona Blackhall, Caroline Dive. Small cell lung cancer circulating tumor cell-derived explants: A new preclinical platform for examining drug response. [abstract]. In: Proceedings of the AACR Special Conference: Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic; Feb 11-14, 2016; New Orleans, LA. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(16_Suppl):Abstract nr IA27.
Evaluation of Angiogenesis and the CD57+ Lymphocytic Population on Bone Marrow Biopsies (BM) in Multiple Myeloma Patients Treated with Thalidomide (Thal)
Authors: Edvan Crusoe, Adriana Quero, Eliana C M Miranda, Manuella Sampaio, Ana Lucia Peres, Flavia Parra, Igor Campos, Carlos S Chiattone, Roberto Pinto Paes, Vania Hungria
Journal: Blood (2011)
Improvement in Renal Function and Its Impact on Survival in Patients with Newly Diagnosed Multiple Myeloma
Authors: Wilson I Gonsalves, Nelson Leung, S. Vincent Rajkumar, Angela Dispenzieri, Francis Buadi, Martha Q. Lacy, David Dingli, Prashant Kapoor, Ronald S. Go, John A Lust, Suzanne R Hayman, Yi Lin, Steven R Zeldenrust, Robert A Kyle, Morie A Gertz, Shaji Kumar
Journal: Blood (2014)
Abstract P3-07-16: ZBTB2 is a novel therapeutic target for cisplatin-resistance in metastatic breast cancer
Authors: V Shin, MT Siu, I Cheuk, J Ho, J Chen, A Kwong
Journal: Cancer Research (2017)

Abstract Background: Zinc finger and BTB/POZ domain containing proteins (ZBTB) belong to a class of DNA-binding proteins that involved in development, differentiation and carcinogenesis. Our earlier findings showed that ZBTB2 expression was upregulated in cisplatin-resistant cells when compared with naïve cells. Increase in ZBTB2 expression was associated with ABCG2 drug transporter in drug resistance. However, the molecular mechanism of ZBTB2 in drug resistance and breast cancer metastasis remain largely unclear. Methods: A cisplatin-resistant triple-negative breast cancer (TNBC) cell line, MDA-MB-231/cis, was used to examine the involvement of drug transporter genes and the drug resistance pathway. Stem cell related genes were studied by RNA-sequencing. Characterization of ZBTB2 on cell proliferation, invasion and epithelial-mesenchymal transition (EMT) process were performed in ZBTB2 siRNA transfected cells. Stem-like cells properties were validated using aldehyde dehydrogenase (ALDH) activity, tumorsphere formation ability and stem cell markers. Metastatic animal model was used to study the genetic changes during metastasis and associated with the findings in clinical samples. Results: ZBTB2 has a higher expression in TNBC than other breast cancer subtypes. Also, the ZBTB2 expression is more prominent in primary breast tumor tissues when compared with non-tumor counterparts from TNBC patients. Silencing of ZBTB2 significantly reduced cell proliferation, invasion and sensitized cells to cisplatin through induction of apoptosis. Induction of ZBTB2 has been associated with breast cancer metastasis in mice model, where higher expression was seen in metastatic tumors when compared with primary tumors from tumor xenografts. ABCG2 and some epithelial-mesenchymal transition (EMT) markers (Twist 1, Snai2 and MMP-9) have been increased in metastatic tumors. Further, RNA sequencing analysis showed that ABCG2, IL6ST and FGFR1 were upregulated in MDA-MB-231/cis cells and downregulated in ZBTB2 siRNA transfected cells. Silencing of ZBTB2 reduced ALDH activity and tumorsphere formation ability. Treatment with inhibitor of NFkB (Bay11-7085) further decreased cell proliferation in cisplatin-resistant cells when compared with siZBTB2 alone. Expression of Stat3 and b-catenin were reduced upon knockdown of ZBTB2. Conclusion: Taken together, silencing of ZBTB2 sensitize cancer cells to cisplatin through regulation of EMT markers and stem-like cell properties in TNBC. These findings suggest a novel molecular pathway targeting ZBTB2/stat3/NFkB signaling to combat drug resistance in metastatic TNBC. Citation Format: Shin V, Siu MT, Cheuk I, Ho J, Chen J, Kwong A. ZBTB2 is a novel therapeutic target for cisplatin-resistance in metastatic breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-07-16.
Spinning Disk Confocal Fluorescent Microscopy (SDCFM) Analyses of Complement Activation Promoted by Anti-CD20 Monoclonal Antibodies (mAbs) Rituximab and Ofatumumab.
Authors: Ronald P. Taylor, Paul V. Beum, Andrew W. Pawluczkowycz, Margaret A. Lindorfer, Frank Beurskens, Jan van de Winkel, Paul Parren
Journal: Blood (2007)
Abstract A18: High-content 3D image analysis of patient-derived organoids
Authors: Erin Spiller, Roy Lau, Sarah Choung, Shannon M. Mumenthaler
Journal: Clinical Cancer Research (2016)

Abstract Organoids are an emerging model system that more closely recapitulates the in vivo environment compared to traditional monolayer systems. Using patient-derived samples grown in a 3D matrix, we hope to advance personalized medicine by providing more patient-specific treatment plans. We have begun building a patient-derived organoid library from primary colon cancer tumors and metastases. Once cells are isolated and seeded into a Basement Membrane Extract (BME) matrix we analyze features on a high content imaging platform, the Operetta (Perkin Elmer). Using the Operetta we are able to obtain quantitative phenotypic data that includes the number, size, and morphology of organoids. In addition, we can capture the dynamics of organoid formation, growth, and death by tracking the same organoids over time using live-cell imaging. More specifically, for each organoid, we capture z-stack images at various heights, and using the Harmony software, we perform quantitative analysis on the maximum projection of the complied images. Using a building block approach, we created a workflow that first relied on identifying regions of interest (ROI), which correspond to organoids. In each ROI we then obtained information such as geometric center, length and width measurements, and texture features. We used this information to determine inter-patient heterogeneity, as well as differences across samples isolated from the primary location (i.e. colon) versus metastatic sites (i.e. liver). After culturing patient-derived organoids for several weeks in laboratory conditions, we perturbed various aspects of the tumor microenvironment (e.g. drug and oxygen levels) and subsequently tracked changes in organoid number, size, and morphology over time. This workflow represents a unique method for image-based quantitative phenotypic analysis of organoids under varying environmental conditions. Citation Format: Erin Spiller, Roy Lau, Sarah Choung, Shannon M. Mumenthaler. High-content 3D image analysis of patient-derived organoids. [abstract]. In: Proceedings of the AACR Special Conference: Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic; Feb 11-14, 2016; New Orleans, LA. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(16_Suppl):Abstract nr A18.
Abstract P2-02-01: Identifying the remaining causes of hereditary breast cancer
Authors: IG Campbell, AH Trainer, L Devereux, PA James, S Rowley, N Li
Journal: Cancer Research (2017)

Abstract Identifying the missing hereditary factors of familial breast cancer could have a major and immediate impact on reducing breast cancer risk in these family members. Up to 1,325 candidate breast cancer predisposition genes, identified through exome sequencing of BRCAx families, were sequenced in index cases of up to 4,000 BRCAx families and 4,000 cancer free women from the LifePool study in Australia. Interrogation of the data to refine the highest priority candidates is ongoing, but it is noteworthy that known (PALB2) or suspected (MRE11A) moderately penetrant breast cancer genes showed enrichment of loss of function (LoF) mutations in this dataset. Conversely, some other recently proposed breast cancer genes (BRIP1 and RINT1) did not show a significantly higher LoF mutation frequency in the cases compared to controls. Based on the number of LoF mutations leading candidates include NTHL1 (12 cases versus 4 controls) and ALKBH1 (7 cases versus 2 controls) which are each important members of the base excision repair and direct nucleotide repair pathways. We examined other genes in the base excision and direct repair pathways that were on our sequencing capture design and observed a significant enrichment of potentially deleterious mutations in 12 genes (NTHL1, OGG1, APEX1, APEX2, NEIL1, NEIL2, NEIL3, MUTYH, MPG, ALKBH1, ALKBH2, ALKBH3): Among the 1,638 cases and 1,654 controls analysed to date, 76 LoF variants were detected in these genes among the cases versus 47 LoF variants among the controls (p=0.007). Based on the overall distribution of variants between cases and controls the probability of selecting 12 genes with such enrichment from the 1,325 genes screened was less than 1 in 200. Our data implicates rare mutations in base excision and direct DNA repair pathways genes as moderate-penetrance breast cancer susceptibility alleles. Citation Format: Campbell IG, Trainer AH, Devereux L, James PA, Rowley S, Li N. Identifying the remaining causes of hereditary breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-02-01.
Eph-B2/Ephrin-B2 Interaction Plays a Major Role In the Adhesion and Survival of WM Cells In the Context of the Bone Marrow Microenvironment
Authors: Feda Azab, Abdel Kareem A. Azab, Patricia Maiso, Phong Quang, Aldo M. Roccaro, Antonio Sacco, Hai T Ngo, Yang Liu, Yong Zhang, Brittany Morgan, Irene M. Ghobrial
Journal: Blood (2010)
Association of Depression and Cardiovascular Disease—Reply
Authors: Matthew S. Freiberg, Jesse C. Stewart, Tasneem Khambaty
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Correction to Address Methodologic Error in Study Reporting Structural Brain Abnormalities in Youth With Psychosis Spectrum Symptoms
Authors: Theodore D. Satterthwaite, Raquel E. Gur
Journal: JAMA Psychiatry (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Development and Validation of a Clinically Based Risk Calculator for the Transdiagnostic Prediction of Psychosis
Authors: Paolo Fusar-Poli, Grazia Rutigliano, Daniel Stahl, Cathy Davies, Ilaria Bonoldi, Thomas Reilly, Philip McGuire
Journal: JAMA Psychiatry (2017)

The overall effect of At Risk Mental State (ARMS) services for the detection of individuals who will develop psychosis in secondary mental health care is undetermined.
Pre-Transplant Ganciclovir and High-Dose Valacyclovir Prophylaxis Decrease Incidence of CMV Reactivation In High-Risk Seropositive UCBT Recipients
Authors: Filippo Milano, Steven Pergam, Hu Xie, Jonathan Gutman, Ivy Riffkin, Victor Chow, Laura Newell, Michael Boeckh, Colleen Delaney
Journal: Blood (2010)
Final Analysis of Overall Survival from the First Trial
Authors: Thierry Facon, Meletios A Dimopoulos, Angela Dispenzieri, John V. Catalano, Andrew Belch, Michele Cavo, Antonello Pinto, Katja Weisel, Heinz Ludwig, Nizar J. Bahlis, Anne Banos, Mourad Tiab, Michel Delforge, Jamie D. Cavenagh, Catarina Geraldes, Je-Jung Lee, Christine Chen, Albert Oriol, Javier De La Rubia, Darrell White, Daniel Binder, Jin Lu, Kenneth C. Anderson, Philippe Moreau, Michel Attal, Jean-Paul Fermand, Herve Avet-Loiseau, Annette Ervin-Haynes, Guang Chen, Vanessa Houck, Cyrille Hulin, Lofti Benboubker
Journal: Blood (2016)
The Vast Majority of CML-CP Patients Treated with Dasatinib (70 mg BID) Who Progress after Long-Term Follow-up (24 mo) Remain in Chronic-Phase
Authors: Jorge Cortes, Michael Mauro, Susan O’Brien, Gautam Borthakur, William Wierda, Yousif Matloub, Ritwik Sinha, David Liu, Hagop Kantarjian
Journal: Blood (2008)